Valeant takes control at Afexa, extends offer; New IMS numbers still show Incivek slowdown;

@FiercePharma: India's Natco inks mAb-sourcing deal with Swiss co., planning to develop 4 biogenerics for India, other Asian markets. More | Follow @FiercePharma

> Valeant Pharmaceuticals ($VRX) ended its Afexa Life Sciences bid with 73.8% of the company, and it's extending its 85-cents-per-share offer through Oct. 27. News

> Vertex Pharmaceuticals ($VRTX) stock dropped on adjusted IMS Health estimates on its hepatitis C drug Incivek, which showed sales hitting a peak in late September and declining slightly thereafter. Item

> India's Natco Pharma inked a deal to source monoclonal antibodies from a Swiss-based company and convert them into four biogeneric drugs for sale in India and other Asian markets. Report

> Abbott Laboratories ($ABT) plans to report third-quarter earnings Wednesday, amid speculation that sales for two of its leading cholesterol drugs are on the decline. Story

> Amgen ($AMGN) tapped President and COO Robert Bradway to join its board, increasing its size to 13 directors. Article

> Novartis ($NVS) launched a ready-to-use formulation of its bone drug Zometa that's easier to use in community settings. Novartis release

> Flamel Technologies set a multiyear supply deal with GlaxoSmithKline ($GSK), agreeing to produce Coreg CR microparticles for the U.K. company. Flamel release

Biotech News

 @FierceBiotech: Third Rock bets $35M on new start-up in risky CNS market, former Lilly R&D head on team. Report | Follow @FierceBiotech

 @JohnCFierce: Is fourth quarter venture funding going to spike after all the moaning and groaning? That would be funny. | Follow @JohnCFierce

 @RyanMFierce: In case you missed it, BBC has neat piece on status of bio batteries that run on water and sugar in the body. Report | Follow @RyanMFierce

 @MaureenFierce: Disgraced South Korean scientist claims to have cloned coyotes, wants to apply tech to endangered species. Story | Follow @MaureenFierce

> MiRagen lands $352M microRNA development pact with Servier. Story

> Google, Kleiner Perkins boost sequencing startup's A round to $33.5M. News

> Third Rock bets $35M on start-up in risky CNS market. Piece

Biotech Research News

> An old drug spurs investigators to think in new ways. Article 

> Stem cell pioneer recognized for drug R&D breakthrough. Report

> Harvard project takes aim at improving drug development odds. Item

Manufacturing News

> GSK site pulls out all stops in plant-investment competition. News

> Senate bill would ease FDA conflict-of-interest rule. Report

And Finally... Researchers identified a species of bacteria prevalent in colon cancer tumors. Report

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.